EX-99.1 2 zeoscientifix_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect Company looks to broaden its Southeast presence to support healthcare providers navigating newly enacted state laws providing for certain stem cell and regenerative medicine therapies. DAVIE, FLORIDA - September 15, 2026 - ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”) today announced its planned expansion into Georgia and Tennessee following the recent enactment by each state of new laws establishing frameworks for certain stem cell and regenerative medicine therapies. The Company believes that this expansion will advance ZEO ScientifiX’s strategy to support healthcare professionals across the Southeast with regenerative biologics, scientific resources, physician education, and responsible implementation support. The expansion builds on ZEO ScientifiX’s existing work with healthcare professionals in Florida who have sought to take advantage of the new Florida law passed in 2025 and the Company’s broader national growth strategy. Georgia House Bill 1275, signed into law on May 11, 2026, a…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Zeo ScientifiX Inc.
ZEOXOTCEQUITYCurrent
Other Events
Item 8.01 Other Events. On September 15, 2026, ZEO issued a press release announcing its planned expansion into Georgia and Tennessee following the recent enactment by each state of new laws establishing frameworks for certain stem cell and regenerative medicine therapies. A copy of the press release is included as Exhibit 99.1 to this Report.
Company context
We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products, including Zofin™, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X™ (“PPX™”), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (“RAAM Products”).